Abstract:Aging induces profound alterations in host biology and correlates with unfavorable clinical outcomes in age-related diseases such as cancer. While the pivotal role of the immune system in regulating tumor progression is well-acknowledged, the precise mechanisms through which aging influences anti-tumor T cell immunity and responsiveness to immune checkpoint blockade (ICB) remain elusive. In this study, we employed syngeneic murine tumor models (B16, MC38, and E0771) in young (2-4 months) and aged (20-24 months) cohorts to elucidate the early impacts of aging on tumor development and T cell responses. Our findings demonstrate that aged mice exhibit accelerated tumor growth across various models. In-depth analysis of tumor-infiltrating lymphocytes (TILs) uncovered distinct alterations in the CD8+ T cell population, characterized by decreased activation status and diminished tumor specificity in aged mice. Correspondingly, aged mice exhibited resistance to anti-PD-1 immunotherapy. To unravel the underlying environmental factors contributing to compromised anti-tumor T cell responses and ICB resistance, we characterized the immune and metabolic landscapes of the aged tumor-draining lymph nodes and tumors. Furthermore, we established a genetically engineered mouse model of lung adenocarcinoma in both young and aged mice, unveiling novel functions and mechanisms associated with age-related T cells actively impeding effective tumor control. In the context of increasing average life expectancy, comprehending the intricate interplay between age-related T cell dysfunction and cancer assumes paramount importance. Such insights hold the key to the development of innovative therapeutic strategies tailored for the growing population of older patients. Citation Format: SeongJun Han, Peter Georgiev, Jaime Schneider, Amy Huang, Zhanel Nugmanova, Thao H. Nguyen, Conghui Yao, Sheila Johnson, Shakchhi Joshi, Ishita Dhiman, Jefte M. Drijvers, Megan Fung, Jared H. Rowe, Brian C. Miller, Gordon J. Freeman, Alison E. Ringel, Marcia C. Haigis, Arlene H. Sharpe. Deciphering the effects of age on T cell immunity and immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6592.

"Boosting" tumor immunity in elderly mice by hyperactivating dendritic cells

Correction of age-associated defects in dendritic cells enables CD4+ T cells to eradicate tumors

Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice

Abstract 6592: Deciphering the effects of age on T cell immunity and immunotherapy

Age-associated contraction of tumor-specific T cells impairs antitumor immunity

The aged tumor microenvironment limits T cell control of cancer

Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer.

Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice

Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice

Harnessing Biomaterials to Amplify Immunity in Aged Mice through T Memory Stem Cells

PD1 blockade improves survival during lethal microbial exposure in old mice

Single-cell sequencing characterizes intratumoral profile of immune cells in old mice

Defective respiration and one-carbon metabolism contribute to impaired naïve T cell activation in aged mice

NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice

Seno-antigen-pulsed dendritic cell vaccine induce anti-aging immunity to improve adipose tissue senescence and metabolic abnormalities

Rejuvenating conventional dendritic cells and T follicular helper cell formation after vaccination

Distinct responses to αPD-1, αPD-L1 and αPD-L2 immunotherapy in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences

B Cells Promote T Cell Immunosenescence and Mammalian Aging Parameters

Boosting T cell immunity against cytomegalovirus: a potential strategy combating human aging and age-related diseases

Hematopoietic aging promotes cancer by fueling IL-1⍺-driven emergency myelopoiesis

4579 Distinct clinical and immunological responses to αPD-1, kαPD-L1 and αPD-L2 immunotherapy in B16 melanoma in aged versus young hosts includes T-cell stem cell effects and PD-L2 expression differences